Table 1 Impact of the COVID-19 pandemic on level and quarterly trend changes in hospital consumption of linezolid and combined Vancomycin/Teicoplanin (DDD/1000 Patient-Days) in a tertiary hospital in Alexandria, Egypt from 2019 to 2023
Term | Hospital Linezolid consumption (DDD/1000PD) | Hospital combined Vancomycin/Teicoplanin consumption (DDD/1000PD |
|---|---|---|
β (95% CI) | β (95% CI) | |
(Intercept) | -5.76 (-57.43, 45.90) | 8.60 (-16.5, 33.70) |
Quarterly trend before COVID-19 | 5.17 (-10.40, 20.75) | 2.86 (-4.71, 10.43) |
Level change after COVID-19 | 95.64 (49.03, 142.26)* | 22.15 (-0.50, 44.79) |
Quarterly trend change after COVID-19 | -7.86 (-23.71, 8.00) | -2.99 (-10.69, 4.72) |